We cloned Xenopus laevis CRISP, XCRISP, a homologue of the mammalian family of cysteine-rich secretory proteins (CRISPs), which has been previously identified as a Wnt3a/noggin responsive gene in an expression screen [Mech. Dev. 87 (1999) 21]. We detected XCRISP expression exclusively in the hatching gland. XCRISP enters the secretory pathway and accumulates on the surface of presumptive hatching gland cells. Overexpression studies of XCRISP and XCRISP-mutants show that XCRISP induces premature hatching of embryos preceded by degradation of the vitelline envelope. A deletion mutant that lacks a 35 amino acid domain even accelerates hatching, while further deletion of the carboxy-terminus reverses these effects. From our studies, we conclude that XCRISP is sufficient to induce degradation of vitelline envelopes and that this activity maps to the most C-terminal amino acids, while the adjacent domain regulates XCRISP activity. q
Introduction
Cysteine-rich secretory proteins (CRISPs), first described in the rodent male genital tract (Cameo and Blaquier, 1976) , have been found in several mammalian and non-mammalian vertebrate species. The main structural characteristics of these evolutionary highly conserved proteins are 16 cysteine residues, 10 of them clustered in the C-terminal half of the protein and the short conserved motifs CGEN(I/H), GHYTQ, Y(Y/F/L)YVC(Q/H)YC, and LCTN (see also Fig. 1 ). Mammalian CRISPs share 50-80% sequence identity (Eberspaecher et al., 1995; Foster and Gerton, 1996; Haendler et al., 1993; Hayashi et al., 1996; Kasahara et al., 1989; Kjeldsen et al., 1996; Kratzschmar et al., 1996; Schambony et al., 1998) , and display still 38 -45% identity to non-mammalian family members like helothermine from the Mexican lizard Heloderma horridum horridum (Morrissette et al., 1995) . More distantly related proteins from insect venoms and of the plant PR 5 family also show significant sequence homologies to CRISPs (Mizuki et al., 1992; Pfisterer et al., 1996) , but do not contain all conserved cysteine residues and motifs.
Three members of the CRISP-family, CRISP-1, CRISP-2, and CRISP-3 have been described in mammals. CRISP-1 and CRISP-2 are secreted predominantly by the glands of the male genital tract and play a role in sperm maturation and sperm-egg fusion (Cohen et al., 1996; . The third member of the mammalian CRISP-family, CRISP-3, shows a wider distribution within the organism, although its function is still obscure. Expression has been detected in several secretory organs like the salivary gland, the pancreas, and the male accessory sexual glands but also in murine pre-B cells, human neutrophils, thymus, colon, and ovary (Haendler et al., 1993; Kratzschmar et al., 1996; Schambony et al., 1998) .
Non-mammalian CRISPs interestingly are found to be venom proteins in snakes, e.g. Trimeresurus mucrosquamatus, Lapemis hardwickii and the Mexican lizard H. horridum horridum. The latter, helothermine, has been shown to block ryanodine receptors of the sarcoplasmic The alignment shows the homology of XCRISP (GenBank accession number AY253453) to members of the CRISP-family, piscivorin (AA062994), T. mucrosquamatus CRVP (P79845), Triflin (Q8JI39), helothermine (Q91055), equine CRISP-3 (O19010), human CRISP-3 (P54108), human TPX-1/CRISP-2 (P16562), equine TPX-1/CRISP-2 (Q8HX97), guinea pig TPX-1/CRISP-2 (Q60477), rat TPX-1/CRISP-2 (O88205), murine TPX-1/CRISP-2 (P16563), human CRISP-1 (P54107), equine CRISP-1 (Q8MHX2), mouse CRISP-1 (Q03401), rat CRISP-1 (P12020), Xenopus Allurin (Q90XE5), and human GliPR (P48060). Conserved amino acids are highlighted in grey and, if conserved in all sequences, marked with an asterisk. Similar amino acids are marked with double dots. Arrows indicate the 16 characteristic and conserved cysteine residues. The C-terminal domain missing in Allurin and replaced by a non-homologous domain in GliPR (boxes), is encoded by a single exon in mammals; e.g. exon 8 in the horse (Giese et al., 2002a) and exon 10 in the mouse (Mizuki et al., 1992) . (B) Phylogenetic tree of vertebrate CRISPs. The tree has been created with the MEGA 2 software from the sequences and alignment shown in (A).
reticulum (Morrissette et al., 1995) . In Xenopus laevis two members of the CRISP-family have been identified. The first, Allurin, is secreted by unfertilised eggs and acts as a chemoattractant for spermatozoa (Olson et al., 2001 ). The second, X. laevis CRISP (XCRISP), first turned up in a screen for Wnt3a and noggin responsive genes together with other dorsal and hatching gland markers like engrailed-2, XA1 and UVS.2 (McGrew et al., 1999) .
We have cloned and sequenced the full-length cDNA of XCRISP. Its spatial and temporal expression pattern suggests a role in hatching of X. laevis embryos. Indeed, our overexpression studies reveal that XCRISP is sufficient to induce degradation of the vitelline envelope and we mapped this activity to the carboxy-terminal region of the protein.
Results

XCRISP shows highest homology to venom proteins
XCRISP mRNA contains one open reading frame of 726 nucleotides coding for a deduced 241 amino acid protein.
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The first 19 amino acids represent a presumptive signal peptide (Nielsen et al., 1997) . Cleavage at the predicted site, S19, gives rise to a mature protein of 222 amino acids with a calculated molecular weight of 24,500 Da.
Comparison of the amino acid sequence of XCRISP with mammalian and non-mammalian CRISPs ( Fig. 1(A) ) shows the highest degree of similarity to equine CRISP-3 (46% identical amino acids) and to several cysteine-rich venom proteins from snake venoms like piscivorin (45% identity), Trimeresus mucosquamatus CRVP (45% identity) and Triflin (44% identity). The first non-mammalian CRISPhomologue from the Mexican lizard H. horridum horridum, helothermine, displays 45% identity with XCRISP. Strikingly, Allurin, the second Xenopus member of the CRISP-family, is considerably shorter than XCRISP. Its C-terminus lacks 36 amino acids including 6 cysteine residues and shares only 38% identical amino acids with XCRISP in the overlapping region. This suggests that XCRISP seems to be closer related to mammalian CRISPs than to Allurin. Phylogenetic analysis of vertebrate CRISPs supports this observation. XCRISP and the proteins from snake venoms form a subbranch of the main branch giving rise to the various mammalian CRISPs, while Allurin and also the human GliPR diverged earlier ( Fig. 1(B) ).
Interestingly, the region that is missing in Allurin is replaced by a entirely different sequence in human GliPR (Fig. 1, boxes) , a glioma related protein (Murphy et al., 1995; Szyperski et al., 1998) . This domain is encoded by a single exon in human and horse crisp genes (Giese et al., 2002a,b; Kasahara et al., 1989; Mizuki et al., 1992; Schwidetzky et al., 1995) . These observations led us to the hypothesis that the carboxy-terminus might represent a functional unit or domain in CRISPs, which has been addressed in our deletion mutant studies.
XCRISP is expressed in the hatching gland
To elucidate the putative function of XCRISP, we first evaluated the temporal and spatial expression patterns during X. laevis embryonic development. In early Xenopus embryos, no expression of XCRISP is detectable, neither by in situ hybridisation nor by RT-PCR. XCRISP is detectable in few distinct cells along the anterior neural fold from stage 16 onwards by in situ hybridisation (Fig. 2) . At neurula stages XCRISP is weakly expressed in two narrow stripes outlining the neural plate ( Fig. 2(A) ). In late neurula and early tadpole stages (Fig. 2(B) and (C)), the XCRISP expressing cells are lined up along the dorso-anterior borders of the closing neural plate to form a y-shaped pattern. Expression increases up to Nieuwkoop and Faber stage 28, accompanied by a narrowing and fusion of the y stem part during neural fold closure (see Fig. 2(C) ). At stage 32 the area stained in in situ hybridisation is more restricted to the head and the number of positive cells has decreased ( Fig. 2(D) ). In later stages up to 40 still few XCRISP expressing cells are detectable on top of the head (not shown). The y-shaped pattern is typical for the hatching gland (Drysdale and Elinson, 1991) and expression pattern of XCRISP partially overlaps with the pattern of XAG (Sive and Bradley, 1996; Sive et al., 1989) , a cement gland and hatching gland marker gene. However, in contrast to XAG, XCRISP is not expressed in the cement gland.
Sections of stage 23 and 28 embryos in Fig. 2 (E) and (F) show that XCRISP expression extends down to the top of the neural tube and that the two distinct areas visible at stage 23 have merged to a single cluster of cells at stage 28.
The presence of XCRISP mRNA has been confirmed by RT-PCR, carried out using two sequence specific primers. Fig. 2(G) shows that an RT-PCR signal is first detected in stage 19 embryos, signal intensity reaches its maximum at stage 28 and then decreases again. In RNA preparations derived from embryos older than stage 35, no RT-PCR product has been obtained. The slight discrepancy to the in situ hybridisation result, a narrower time range of mRNA detection, is presumably due to the sensitivity of the techniques applied. RT-PCR has been performed on total RNA preparations and samples have been normalised with respect to the amount of total RNA used for the Reverse Transcription step. As can be seen from the in situ hybridisation, signals are weak and restricted to a few cells in embryos before stage 19 and after stage 35. Although XCRISP mRNA can be detected in the positive cells by in situ hybridisation, the absolute amounts of XCRISP mRNA present in total RNA preparations of whole embryos might be too low in these cases.
Nevertheless, XCRISP is expressed specifically in the presumptive hatching gland and its temporal expression seems to coincide with the time embryos hatch from their vitelline envelope. Therefore, XCRISP can be considered to be a specific hatching gland marker and might play a role in the hatching process.
XCRISP regulates hatching of embryos
To further elucidate the function of XCRISP we carried out overexpression studies. Besides the full-length construct, we created two deletion mutants based on the observation that Allurin lacks the carboxy-terminal region. As this domain is furthermore encoded by a single exon in mammals, it might represent a functional unity. We first deleted a region spanning the six carboxy-terminal cysteine residues between Cys 200 and Cys 235 (XCRISP D200 -235). The second mutant, XCRISP D200 -241, lacks the complete carboxy-terminal region, amino acids 200-241 ( Fig. 3(A) ). In addition to these, we also constructed carboxy-terminal fusions of full-length XCRISP with GFP and six myc-epitopes, respectively.
Injection of full-length XCRISP RNA in both dorsal blastomeres at the four-cell stage results in premature hatching of embryos about two stages earlier than wild type. As shown in Fig. 3(B) , injection of XCRISP D200 -235 even enhances this effect, inducing hatching again about one stage earlier compared with embryos overexpressing full-length XCRISP. Upon further deletion of the remaining six carboxy-terminal residues in Fig. 3 . Overexpression of XCRISP and a C-terminal deletion mutant induce premature hatching of Xenopus embryos. (A) Mutants have been generated by site directed mutagenesis from full-length XCRISP including the putative signal peptide. XCRISP D200-235 lacks amino acids 200 -235 corresponding to the C-terminal domain. In XCRISP D200-241 additionally the six carboxy-terminal amino acids have been deleted, creating a mutant that lacks the complete region encoded by the last exon in mammalian genes (see Fig. 1 ). To allow detection of XCRISP, C-terminal fusion proteins with GFP or 6x myc-epitope have been created. (B) Hatching times and stages of embryos injected in both cells in the two-cell stage with 500 pg XCRISP (light grey), XCRISP D200 -235 (medium grey), or XCRISP D200-241 (dark grey) have been normalised against the respective uninjected controls (white). The data shown are mean values from three experiments each (see also XCRISP D200 -241 the hatching time is restored to that of uninjected controls ( Fig. 3 (B) and Table 1 ). We further observed that premature hatching of embryos injected with full-length XCRISP and XCRISP D200 -235 goes along with structural weakness of the vitelline envelope. The effect is detectable from late neurula stages onwards, when the anterior -posterior axis elongates. Envelopes of wild type embryos are firm and tense until hatching and force the elongating embryo to coil itself inside the envelope. In contrast, vitelline envelopes of embryos overexpressing XCRISP appear soft and weak. Embryos do not coil up, but stretch their envelope during anterior -posterior elongation (Fig. 4) . Again, the phenotype is not observed when XCRISP D200 -241 is injected (not shown). In the latter case the vitelline envelopes look normal and tense until hatching.
To better visualise the hatching process and the status of vitelline envelopes, we coated embryos with fluorescent polystyrene beads at stage 19 to 20. Although at this stage all embryos still have a spherical form, the differences between envelopes of injected and uninjected embryos are already visible. While the vitelline envelopes of wild type embryos are almost uniformly coated, the fluorescent beads bind much weaker to the envelopes of embryos injected with XCRISP (Fig. 5) . To monitor the further development and hatching, images were taken in 15 min intervals until the embryos reached stage 28. Fig. 5 shows merged fluorescent and bright field images in hourly spacing. Embryos overexpressing full-length XCRISP and XCRISP D200 -235 show weak vitelline envelopes that stretch with anterior-posterior elongation of the embryos (Fig. 5(B) , white arrows). As seen in Fig. 5 (B) and (C) the XCRISP D200 -235 injected embryos are the first to hatch, at about stage 25, followed by those injected with full-length XCRISP at about stage 26 (Fig. 5(F) and (G)). One embryo injected with full-length XCRISP seems to hatch already at the beginning of the experiment (Fig. 5(A) ), because its vitelline envelope has been damaged during handling (arrowhead). The increased susceptibility to damage is another indicator of the lack of structural integrity of envelopes in XCRISP-injected embryos. At stage 27 all injected embryos are hatched and start to move around, while the uninjected control embryos are still coiled up inside their envelopes and show no weakening of vitelline envelope ( Fig. 5(H) ).
XCRISP affects hatching indirectly
Considering the described effects on vitelline envelopes and hatching time, we asked for the mechanism of XCRISP action. First we confirmed the presence of the overexpressed proteins throughout the observation period. Myc-tagged versions of XCRISP proved to induce the same phenotypes as the non-tagged constructs upon overexpression. The fulllength myc-fusion construct is detected in whole embryo lysates up to stage 27 ( Fig. 6(A) ). Two bands of 36 and 34 kDa are stained, which is in agreement with the predicted molecular weights of the precursor and processed fusion proteins, respectively, assuming removal of the predicted signal peptide. The presence of unprocessed protein at stage 27 shows that the injected XCRISP RNA is still translated at that stage, the normal hatching time. We further tested whether XCRISP, presumptively a secreted protein, is directly interacting with the vitelline envelope. Western blotting of vitelline envelopes isolated at stage 23 and 26, before and after hatching of the embryos, show that XCRISP does not bind to the egg envelope.
We further investigated the subcellular localisation of XCRISP by overexpression of a GFP-tagged construct. Explants of the hatching gland and of the ventral epidermis of stage 26 embryos and cross-sections of embryos at the same stage have been examined for XCRISP-GFP by confocal microscopy. As expected for a secreted protein, XCRISP-GFP is detected in the secretory pathway, endoplasmic reticulum, Golgi apparatus and in secretory vesicles inside the cells in dorsal and ventral explants ( Fig. 6(B) and (C), white arrows). On the ventral epidermis, XCRISP-GFP is also found weakly associated with the cell membrane of all cells, giving rise to a patchy, punctual localisation. In dorsal explants, however, the association with the cell membrane is stronger and the protein is uniformly distributed all over the outer membrane of a subset of cells (Fig. 6(B) ). Interestingly, not all cells show fluorescence on the cell membrane in the dorsal explants. This might indicate a localised accumulation by binding to an interaction partner or local regulation of protein stability on the dorsal side. This is better observed in the cross-sections counterstained with an anti-E-cadherin antibody. Here, it is clear that XCRISP-GFP accumulates at the apical surface of hatching gland cells, which are distinguishable from the epidermis by their shape and in the transmission image also by the distribution of melanin pigments.
XCRISP is sufficient to induce degradation of the vitelline envelope
It has been reported, that hatching in Xenopus embryos is initiated by the release of Xenopus hatching enzyme (XHE), a protease (Fan and Katagiri, 2001 ) which cleaves specifically ZPAX (Lindsay et al., 2001) . Proteolytic cleavage of ZPAX weakens the network structure of the vitelline envelope and allows the embryo to hatch. Release of XHE is assumed to be dependent on connexin 30 containing gap junctions (Levin and Mercola, 2000) . In our hands, however, gap junction inhibiting drugs such as heptanol, glycyrrhetinic acid and anandamide did not have any effect on the hatching time of XCRISP-injected embryos (data not shown). Although the overall protease activity as detected by casein digestion in the medium of injected and uninjected embryos does not differ significantly (not shown), the effects observed in our studies indicate a role of XCRISP in hatching especially affecting the stability of the vitelline envelope. Although XCRISP itself does not interact with the vitelline envelope, it might be indirectly involved in this process.
To verify if weakening of the vitelline envelope indeed correlates with its specific degradation, that is ZPAX cleavage, embryonic envelopes collected at different stages have been analysed by SDS-PAGE. A constant composition of proteins up to hatching is observed for control embryos. A characteristic pattern of degradation products is visible at the time of hatching around stage 28 and 29 as indicated by arrows in Fig. 7(A) . In contrast to the wild type, envelopes of XCRISP-injected embryos fail to show any alterations in the band pattern around their hatching time at stage 26, but the characteristic degradation pattern is detectable as early as stage 18 (Fig. 7(B) ). From the SDS-PAGE it could be assumed that, like in wild type embryos, the cleavage of the egg envelope proteins takes place at a definite time point, however, much earlier in development. The low molecular weight products of this proteolytic degradation are probably quickly lost by diffusion into the medium and therefore no longer present in envelopes of later stages. At stage 18, expression of endogenous hatching gland specific markers like XCRISP itself but also XHE starts (Katagiri et al., 1997) , so it is possible that the observed effects are due to premature release and activation of XHE.
We carried out mass spectrometrical analyses to confirm the identity of the main bands larger than 31 kDa seen at stage 28 in control embryos (Fig. 8) . The reported major components of Xenopus vitelline envelopes, ZPAX, ZPB/ gp37, and ZPC/gp43 have been identified in the bands corresponding to their expected molecular weight ( Table 2) . As these are highly glycosylated proteins, only a relatively small number of unmodified peptides are detectable. Besides these vitelline envelope glycoproteins, vitellogenin A2 precursor, lipovitelline and cortical granule lectin have been found as contaminants, probably due to damage inflicted on the embryos during manual removal of the envelopes and the abundant presence of these proteins. ZPAX has been identified in the degradation bands C01 -C04 and C06 by a single peptide, confirming that ZPAX is the vitelline envelope component primarily affected by enzymatic degradation. As this is a specific event, XHE cleaves ZPAX only at specific recognition sites, these results confirm, that the effects induced by XCRISP overexpression are due to an early induction of the endogenous hatching process and not by any other mechanism. In the latter case, we would not expect to observe the same degradation products, but an altered pattern. Table 2 Proteins identified by mass spectrometry in the bands from Fig. 7 From these observations we assume that XCRISP is sufficient to induce or activate the degradation mechanism of the vitelline envelope as soon as endogenous expression of degradation enzymes starts.
Discussion
The restricted temporal and spatial expression pattern of XCRISP in hatching gland cells, which overlaps with other hatching gland markers like XAG (Sive and Bradley, 1996; Sive et al., 1989 ) and the hatching enzyme XHE (Katagiri et al., 1997) , indicates a role of XCRISP in hatching of Xenopus embryos. The mechanism of XCRISP function seems to be indirect, as the protein does not associate with the vitelline envelope itself, but is found in the secretory pathway and associated with the plasma membrane of hatching gland cells. This is in good agreement with the fact that although the mammalian homologues have been subject to extensive studies, an enzymatic activity of CRISPs has never been identified. On the other hand, association with the cell membrane as we show for XCRISP has also been reported for rat and horse CRISPs, which are found on spermatogonia and spermatozoa (Brooks et al., 1986; Brooks and Tiver, 1983; Schambony et al., 1998) . How this association to plasma membranes is mediated remains to be shown, but neither XCRISP nor any other member of the CRISP-family identified so far contains a membrane anchoring or transmembrane domain. Association with cell membranes could be mediated by interaction with membrane surface groups or a specific receptor.
Our data shows that XCRISP is able and sufficient to induce premature hatching of embryos and that the carboxyterminal domain plays a crucial role in this process, while we did not observe any influence of gap junction blockers (Levin and Mercola, 2000) . Overexpression of full-length XCRISP is sufficient to induce degradation of ZPAX presumably by inducing the release or activation of hatching related enzymes like XHE (Lindsay et al., 2001 ). An effect on the expression of these enzymes cannot be ruled out from our data, but seems unlikely as it has been shown that the hatching gland specific genes XA-1 and UVS.2 are controlled by Wnt/noggin signalling pathways (McGrew et al., 1999) . Deletion of amino acids 200-235 yields the same phenotype considering the stability and integrity of the vitelline envelope, but embryos hatch even one stage earlier.
Additional deletion of the carboxy-terminal amino acids 236 -241, mutant XCRISP D200 -241, restores structural integrity of the vitelline envelope and hatching time does not differ significantly from that of uninjected controls. Therefore, we conclude that the carboxy-terminal six amino acid tail is essential for XCRISP-mediated premature degradation of ZPAX and weakening of vitelline envelopes.
The hatching process in Xenopus involves on one hand local degradation and weakening of the vitelline envelope and on the other hand mechanical force from elongation and movement of the embryos to break through. XCRISP and XCRISP D200 -235 seem to induce not only local but general degradation of the egg envelope, which makes them susceptible to damage by any force applied by the embryo or during handling. In the case of XCRISP, hatching takes place when embryos show the first spontaneous movements at stage 26 (Nieuwkoop and Faber, 1975) . The already weakened envelope is broken up as soon as embryos start to move. Nevertheless, this does not explain the even earlier hatching induced by XCRISP D200 -235. Although embryos start to move upon external stimulation already at stage 24, this cannot account for these differences, as all embryos are subjected to the same handling. Another force generating event is the elongation of the embryonic body axis, however, XCRISP D200-235 injected embryos never appeared significantly larger than control and XCRISP-injected embryos. So the mechanism of XCRISP D200-235 action stays obscure.
However, the domain deleted in XCRISP D200 -235 including the six carboxy-terminal cysteine residues might represent a functional unit or domain, as its deletion induces significant acceleration of the hatching process. Interestingly, the region spanning the six carboxy-terminal cysteines shows homology to potassium-channel blocking peptide toxins like Sh-toxin from the sea anemone Stichodactyla helianthos (Castaneda et al., 1995) and is also conserved in non-mammalian venom proteins. Amino acids 200 -235 of XCRISP and Sh-toxin share 25% identical amino acids including all six cysteine residues. The homology is further supported by structural similarities (M. Gentzel, unpublished data). Furthermore, the CRISP helothermine acts by blocking ryanodine receptors of the sarcoplasmic reticulum (Morrissette et al., 1995) . Four CRISPs recently identified as snake venom proteins have been shown to block muscle contraction, and another two homologues from snake venoms act on cyclic-nucleotide gated ion channels (Morrissette et al., 1995; Yamazaki et al., 2002a,b) .
Although it remains to be investigated in greater detail, whether the carboxy-terminal domain of CRISPs plays a role in these effects on ion channels, our study shows that XCRISP induces the degradation of the vitelline envelope, presumably by triggering the release or activation of lytic enzymes. We identified ZPAX as one component subject to degradation, which points towards XHE as the activated enzyme, as it has been shown that ZPAX is a substrate of XHE (Lindsay et al., 2001) . Furthermore, partial digestion of the vitelline envelope by XHE is assumed to be a prerequisite to hatching (Urch and Hedrick, 1981) . Our results suggest that XCRISP overexpression is sufficient to cause this effect. We further show that a carboxy-terminal toxin-homologous domain spanning six cysteine residues plays a regulatory role while the last six amino acids (236 -241) are required to trigger ZPAX degradation.
Experimental procedures
RNA purification and RT-PCR
Total RNA was isolated from whole embryos using TriZol Reagent (Invitrogen GmbH, Karlsruhe, Germany) following the manufacturer's instructions. Poly(A) þ RNA has been further purified from total RNA preparations using the NucleoTrap mRNA kit (Macherey Nagel, Düren, Germany).
The full-length cDNA sequence has been obtained by a RACE procedure following the instructions for the Marathon cDNA Amplification Kit (Clontech Laboratories, Palo Alto, CA). Nested primers have been used for amplification of 5 0 -and 3 0 -RACE products: 5 0 -cacccacaactcctacaggaggaatgc-3 0 and 5 0 -ggaatggtgcgttgatctgatggc-3 0 . For RT-PCR amplification 1 mg of total RNA has been reverse transcribed with SUPERSCRIPT II Reverse Transcriptase (Invitrogen GmbH, Karlsruhe, Germany) and a 245 bp fragment has been amplified using the primers 5 0 -ccactgtcagacagaccattg-3 0 and 5 0 -ccatgctgaatggctcctc-3 0 with Taq polymerase (Promega GmbH, Mannheim, Germany) following standard PCR procedures.
In situ hybridisation
A 245 bp fragment of XCRISP has been amplified as described above. This 245 bp fragment, cloned into pGEM-T and sequenced, served as a template for the generation of in situ probes. The XAG probe has been kindly provided by Hazel Sive (Sive and Bradley, 1996; Sive et al., 1989) . In situ hybridisations have been carried out as described previously (Hollemann et al., 1999) with the following alterations: An anti-fluorescein horsereddish-peroxidase conjugate (Roche Molecular Biochemicals, Mannheim, Germany) and an anti-digoxigenin alkaline phosphatase conjugate (Roche Molecular Biochemicals, Mannheim, Germany) have been applied simultaneously in 1:500 and 1:2000 dilutions, respectively. After three washing steps in TBST, the digoxigenin-signal has been developed first. The embryos have been prewashed for 5 min in substrate buffer followed by incubation in NBT/BCIP solution (Roche Molecular Biochemicals, Mannheim, Germany). Colour development has been stopped by three washes with TBST after the signal was clearly visible. Development of the fluorescein-signal has been carried out identically, prewash of 5 min in substrate buffer followed by colour development, using the AEC staining kit (Sigma, Taufkirchen, Germany).
Microinjections
Full-length and C-terminally deleted XCRISP and Cterminal fusion proteins with 6x myc or GFP have been cloned in pCS2 þ vectors. RNA for microinjections has been prepared from Not I linearised plasmids using the mMessage mMachine Kit (Ambion, Austin, TX) and purified by Gelfiltration on G50 micro spin columns (Amersham Pharmacia Biotech, Uppsala, Sweden). Embryos were obtained by in vitro fertilisation, cultivated and injected as described previously (Geis et al., 1998) , and staged according to the normal table of Nieuwkoop and Faber (Nieuwkoop and Faber, 1975) . Two-or four-cell stage embryos have been injected with 500 pg of purified RNA per blastomeres in both or the two dorsal cells and cultivated to the desired stage.
SDS-PAGE and Western blotting of envelopes and embryonic extracts
Vitelline envelopes have been manually removed from embryos, washed in CMF-MBS containing 2 mM EDTA and 1 mM PMSF and collected by centrifugation. Residual buffer has been removed by vacuum concentration. Proteins of the embryonic envelope have then been solubilised by heating to 95 8C in SDS sample buffer and separated by SDS-PAGE. Gels have been stained using Coomassie Brilliant Blue or the Silver Stain Plus Kit (BioRad, Hercules, CA). Whole embryos have been lysed in NOPbuffer (10 mM HEPES pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40) supplemented with complete w protease inhibitor cocktail (Roche Molecular Biochemicals, Mannheim, Germany). Lysates were delipidised by extraction with 1,1,2-Trifluor-trichlorethane and denatured by boiling in SDS sample buffer.
For Western blotting procedures, proteins were transferred to Nitrocellulose membranes and incubated in undiluted 9E10 cell culture supernatant to detect mycAntigens, followed by incubation with Alkaline Phosphatase labelled goat-anti-mouse IgG (Dianova, Hamburg, Germany) and colour development using the NBT/BCIP AP-substrate (Roche Molecular Biochemicals, Mannheim, Germany).
Hatching gland explants and immunohistology
Embryos were injected with 500 pg XCRISP-GFP in both blastomeres at the two-cell stage and cultivated till stage 26. Embryos were manually stripped of their vitelline envelopes and explants of the dorsal ectoderm containing the presumptive hatching gland were prepared. Similar areas of the ventral epidermis served as control explants. The explants were mounted on slides with Elvanol and examined with a confocal laser scanning microscope (LSM-SP Leica, Bensheim, Germany).
For cross-sections embryos were fixed in 4% buffered formaldehyde for 1 h and embedded in 3% agarose. Vibratome sections were prepared, blocked with 10% horse serum in PBS and stained for E-cadherin using a monoclonal anti-E-cadherin antibody (3H10) and an antimouse Cy3 secondary antibody. Sections were mounted in Elvanol and examined with a confocal laser scanning microscope (LSM-SP Leica, Bensheim, Germany).
In vivo labelling of vitelline envelopes
Vitelline envelopes of living embryos have been coated with Fluo Spheres w (Molecular Probes Inc., Eugene, OR) using 10 ml bead suspension per 500 ml 50 mM MOPS pH 6.0 for 15 min with gentle shaking. Excess beads have been rinsed off with 0.1 £ MBS. For time lapse microscopy, embryos were cultured in 0.1 £ MBS and brightfields and fluorescence images collected every 10 min using a Leica binocular microscope (Leica, Bensheim, Germany), equipped with epifluorescence optics and OpenLab imaging software (Improvision, Coventry, UK).
Mass spectrometry
Unless stated otherwise, all chemicals were of analytical grade or better. Proteins separated by SDS-polyacrylamide gel electrophoresis were digested in gel with sequencing grade trypsin (Roche Molecular Biochemicals, Mannheim, Germany) according to Shevchenko et al. (1996 Shevchenko et al. ( , 1997 . Isotopical labelling with 18 O for de novo sequencing was achieved by digestion in buffer containing 50% H 2 18 O (Phychem, Düren, Germany) (Shevchenko et al., 1996 (Shevchenko et al., , 1997 . Peptide mixtures were separated by Reversed-phase HPLC-MSMS using a nanoflow HPLC system (Ultimate, LC Packings, Idstein, Germany) directly interfaced to a QTof 1 mass spectrometer (Micromass, Manchester, UK) as described previously (Hartmuth et al., 2002) .
